Gastric Bypass

Adults with obesity and type 2 diabetes who underwent bariatric surgery or a low-calorie diet intervention experienced similar metabolic benefits, with no evident clinically important effects independent of weight loss, study data show.

For patients with type 2 diabetes and obesity, undergoing Roux-en-Y gastric bypass surgery led to greater remission rates of albuminuria and early stage chronic kidney disease compared with best medical care.

Adolescents and young adults with obesity who underwent sleeve gastrectomy experienced a reduction in bone mineral density measures in the year after surgery when compared with nonsurgical controls, but did not experience a decrease in bone strength despite significant weight loss, according to findings published in Bone.

Adolescents with type 2 diabetes and obesity may be at lower risk for developing diabetic kidney disease if they receive bariatric surgery compared with medical treatment alone for diabetes, according to findings published in Diabetes Care.

LAS VEGAS — Adults who undergo bariatric surgery may be more likely to be readmitted to the hospital, have more trips to the ICU and have a higher rate of overall morbidity if they have an HbA1c of more than 7% before surgery, according to findings presented at ObesityWeek.

LAS VEGAS — Liver fat volume can be reduced by bariatric surgery regardless of procedure type, although some liver enzymes may be affected differently by sleeve gastrectomy or Roux-en-Y gastric bypass, according to findings presented at ObesityWeek.

Adults with obesity and type 1 diabetes may be at lower risk for cardiovascular death, heart failure, stroke and cardiovascular disease after bariatric surgery, although hyperglycemia and hypoglycemia risks may rise as well, according to findings presented at the European Association for the Study of Diabetes annual meeting.

In a cohort of adults who underwent bariatric surgery, 73% had at least one nutritional deficiency 5 years later even though 73% reported taking a dietary supplement, according to findings published in Bariatric Surgical Practice and Patient Care.

Before 2015, managing obesity was the realm of other specialties. Although gastroenterologists have traditionally dealt with some of the comorbidities of obesity, they were not in position to target the root cause and provide relief in the form of weight management. That changed with the clinical introduction and FDA approval of several devices and procedures for the endoscopic management of obesity and metabolic disease, putting GIs right in the middle of the obesity epidemic.

Obesity is a rapidly increasing problem in the United States and worldwide, with more than 30% of adult Americans now affected. Unfortunately, we are lacking in effective therapies to promote significant weight loss.